Effect of molecular subtypes on radiotherapy response in patients with breast cancer brain metastasis
Objective: This study aimed to investigate survival and the response to radiotherapy (RT) among patients with molecular subtypes of breast cancer brain metastases. Patients and Methods: We retrospectively analyzed the data of 139 breast cancer patients with brain metastases treated with wholebrain radiotherapy (WBRT) or focal brain treatment (FBT) between 2006 and 2019. Overall survival (OS) and brain metastasis progression-free survival (BMPFS) were calculated from the first RT until death or the last follow-up. Survival analyses were performed using the Kaplan–Meier method. Prognostic factors were evaluated using the Cox proportional hazard model. Results: Twenty three (16.5%), 77 (55.4%), 14 (10.1%), and 25 (18%) patients were diagnosed with triple-negative, HER-2 (+), luminal-like A, and luminal-like B breast cancer, respectively. Of 139 patients, 66 (47.8%) underwent FBT, and 73 (52.5%) underwent WBRT. While the most preferred fraction was 10*300 Gy in WBRT, doses of 15-25 Gy in 1-5 fractions were preferred in local RT. We observed that age, Karnofsky performance scale (KPS) score, initial RT technique, extracranial disease, number of brain metastases impacted OS and BMPFS. Conclusion: Breast cancer brain metastasis is a different, complex, and challenging disease based on the molecular subtype of the tumor, despite various local treatments. Therefore, appropriate and tailored treatment approaches should be considered for the different molecular subtypes.
___
- [1] Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and
survivorship statistics, 2012. CA Cancer J Clin 2012; 62:220-
41. doi: 10.3322/caac.21149. Epub 2012 Jun 14.
- [2] Hofer S, Pestalozzi BC. Treatment of breast cancer brain
metastases. Eur J Pharmacol 2013; ;717: 84-7. doi: 10.1016/j.
ejphar.2012.11.068.
- [3] Lin NU, Bellon JR, Winer EP. CNS metastases in breast
cancer. J Clin Oncol 2004 Sep; 22: 3608-17. doi: 10.1200/
JCO.2004.01.175.
- [4] Miller KD, Weathers T, Haney LG, et al. Occult central nervous
system involvement in patients with metastatic breast cancer:
prevalence, predictive factors and impact on overall survival.
Ann Oncol 2003; 14: 1072-7. doi: 10.1093/annonc/mdg300.
- [5] Gaspar L, Scott C, Rotman M, et al. Recursive partitioning
analysis (RPA) of prognostic factors in three Radiation
Therapy Oncology Group (RTOG) brain metastases trials. Int
J Radiat Oncol Biol Phys 1997; 37: 745-51. doi: 10.1016/s0360-
3016(96)00619-0.
- [6] Takahashi H, Isogawa M. Management of breast cancer brain
metastases. Chin Clin Oncol 2018; 7: 30. doi: 10.21037/
cco.2018.05.06.
- [7] Miller JA, Kotecha R, Ahluwalia MS, et al. Overall survival and
the response to radiotherapy among molecular subtypes of
breast cancer brain metastases treated with targeted therapies.
Cancer 2017; 123: 2283-2293. doi: 10.1002/cncr.30616.
- [8] Sperduto PW, Kased N, Roberge D, et al. The effect of tumor
subtype on the time from primary diagnosis to development of
brain metastases and survival in patients with breast cancer. J
Neurooncol 2013; 112: 467-72. doi: 10.1007/s11060.013.1083-
9.
- [9] Yerushalmi R, Woods R, Kennecke H, Speers C, Knowling M,
Gelmon K. Patterns of relapse in breast cancer: changes over
time. Breast Cancer Res Treat 2010; 120: 753-9. doi: 10.1007/
s10549.009.0510-2.
- [10] Gradishar WJ, Moran MS, Abraham J, et al. NCCN Guidelines®
Insights: Breast Cancer, Version 4.2021. J Natl Compr Canc
Netw 2021; 19: 484-93. doi: 10.6004/jnccn.2021.0023.
- [11] Brown PD, Jaeckle K, Ballman KV, et al. Effect of radiosurgery
alone vs radiosurgery with whole brain radiation therapy on
cognitive function in patients with 1 to 3 brain metastases:
A randomized clinical trial. JAMA 2016; 316: 401-9. doi:
10.1001/jama.2016.9839.
- [12] Brown PD, Ballman KV, Cerhan JH, et al. Postoperative
stereotactic radiosurgery compared with whole brain
radiotherapy for resected metastatic brain disease (NCCTG
N107C/CEC·3): a multicentre, randomised, controlled, phase
3 trial. Lancet Oncol 2017; 18: 1049-60. doi: 10.1016/S1470-
2045(17)30441-2.
- [13] Leone JP, Leone BA. Breast cancer brain metastases: the last
frontier. Exp Hematol Oncol 2015 24; 4: 33. doi: 10.1186/
s40164.015.0028-8.
- [14] Kress MA, Oermann E, Ewend MG, et al. Stereotactic
radiosurgery for single brain metastases from non-small cell
lung cancer: progression of extracranial disease correlates
with distant intracranial failure. Radiat Oncol 2013; 8: 64. doi:
10.1186/1748-717X-8-64.
- [15] Coates AS, Winer EP, Goldhirsch A, et al., and Panel Members.
Tailoring therapies—improving the management of early
breast cancer: St Gallen International Expert Consensus on
the Primary Therapy of Early Breast Cancer 2015. Ann Oncol
2015; 26: 1533-46. doi: 10.1093/annonc/mdv221.
- [16] Darlix A, Louvel G, Fraisse J, et al. Impact of breast cancer
molecular subtypes on the incidence, kinetics and prognosis
of central nervous system metastases in a large multicentre
real-life cohort. Br J Cancer 2019; 121: 991-1000. doi: 10.1038/
s41416.019.0619-y.
- [17] Mills MN, Figura NB, Arrington JA, et al. Management of
brain metastases in breast cancer: a review of current practices
and emerging treatments. Breast Cancer Res Treat 2020; 180:
279-300. doi: 10.1007/s10549.020.05552-2.
- [18] Wang R, Zhu Y, Liu X, Liao X, He J, Niu L. The
Clinicopathological features and survival outcomes of patients
with different metastatic sites in stage IV breast cancer. BMC
Cancer 2019; 19: 1091. doi: 10.1186/s12885.019.6311-z.
- [19] Rudat V, El-Sweilmeen H, Brune-Erber I, et al. Identification
of breast cancer patients with a high risk of developing brain
metastases: a single-institutional retrospective analysis. BMC
Cancer 2014; 14: 289. doi: 10.1186/1471-2407-14-289.
- [20] Shen Q, Sahin AA, Hess KR, et al. Breast cancer with brain
metastases: clinicopathologic features, survival, and paired
biomarker analysis. Oncologist 2015; 20: 466-73. doi: 10.1634/
theoncologist.2014-0107.
- [21] Yan M, Lü HM, Liu ZZ, et al. High risk factors of brain
metastases in 295 patients with advanced breast cancer. Chin
Med J (Engl) 2013; 126: 1269-75. PMID: 23557557.
- [22] Sperduto PW, Kased N, Roberge D, et al. Effect of tumor
subtype on survival and the graded prognostic assessment
for patients with breast cancer and brain metastases. Int
J Radiat Oncol Biol Phys 2012; 82: 2111-7. doi: 10.1016/j.
ijrobp.2011.02.027.
- [23] Leone JP, Leone BA. Breast cancer brain metastases: the
last frontier. Exp Hematol Oncol 2015; 4:33. doi: 10.1186/
s40164.015.0028-8.
- [24] Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific
prognostic factors, indexes, and treatment outcomes for
patients with newly diagnosed brain metastases: a multiinstitutional
analysis of 4,259 patients. Int J Radiat Oncol Biol
Phys 2010; 77: 655-61. doi: 10.1016/j.ijrobp.2009.08.025.
- [25] Caballero JA, Sneed PK, Lamborn KR, et al. Prognostic factors
for survival in patients treated with stereotactic radiosurgery
for recurrent brain metastases after prior whole brain
radiotherapy. Int J Radiat Oncol Biol Phys 2012; 83: 303-9. doi:
10.1016/j.ijrobp.2011.06.1987.
- [26] Firlik KS, Kondziolka D, Flickinger JC, Lunsford LD.
Stereotactic radiosurgery for brain metastases frombreast
cancer. Ann Surg Oncol 2000; 333-8. doi: 10.1007/
s10434.000.0333-1
- [27] Muacevic A, Kreth FW, Tonn J-C, Wowra B. Stereotactic
radiosurgery for multiple brain metastases from breast
carcinoma. Cancer 2004; 100:1705-11. doi: 10.1002/cncr.20167
- [28] Kased N, Binder DK, McDermott MW, et al. Gamma Knife
radiosurgery for brain metastases from primary breast cancer.
Int J Radiat Oncol Biol Phys 2009; 75: 1132-40. doi: 10.1016/j.
ijrobp.2008.12.031.
- [29] Jaboin JJ, Ferraro DJ, DeWees TA, et al. survival following
gamma knife radiosurgery for brain metastasis from breastcancer.
Radiat Oncol 2013; 8:131. doi: 10.1186/1748-717X-8-
131.
- [30] Kim YJ, Kim JS, Kim IA. Molecular subtype predicts incidence
and prognosis of brain metastasis from breast cancer in SEER
database. J Cancer Res Clin Oncol 2018; 144: 1803-16. doi:
10.1007/s00432.018.2697-2.
- [31] Rudat V, El-Sweilmeen H, Brune-Erber I, et al. Identification
of breast cancer patients with a high risk of developing brain
metastases: a single-institutional retrospective analysis. BMC
Cancer 2014; 14: 289. doi: 10.1186/1471-2407-14-289.
- [32] Kuba S, Ishida M, Nakamura Y, et al. Treatment and prognosis
of breast cancer patients with brain metastases according to
intrinsic subtype. Jpn J Clin Oncol 2014; 44: 1025-31. doi:
10.1093/jjco/hyu126.
- [33] Chong JU, Ahn SG, Lee HM, et al. Local control of brain
metastasis: treatment outcome of focal brain treatments in
relation to subtypes. J Breast Cancer 2015; 18: 29-35. doi:
10.4048/jbc.2015.18.1.29.
- [34] Fokas E, Henzel M, Hamm K, Grund S, Engenhart-Cabillic R.
Brain metastases in breast cancer: analysis of the role of HER2
status and treatment in the outcome of 94 patients. Tumori
2012; 98: 768-74. doi: 10.1700/1217.13502.
- [35] Hines SL, Vallow LA, Tan WW, McNeil RB, Perez EA, Jain
A. Clinical outcomes after a diagnosis of brain metastases
in patients with estrogen – and/or human epidermal growth
factor receptor 2-positive versus triple-negative breast cancer.
Ann Oncol 2008; 19: 1561-5. doi: 10.1093/annonc/mdn283.
- [36] Cho E, Rubinstein L, Stevenson P, et al. The use of stereotactic
radiosurgery for brain metastases from breast cancer: who
benefits most? Breast Cancer Res Treat 2015 Feb; 149: 743-9.
doi: 10.1007/s10549.014.3242-x.
- [37] Hicks DG, Short SM, Prescott NL, et al. Breast cancers with
brain metastases are more likely to be estrogen receptor
negative, express the basal cytokeratin CK5/6, and overexpress
HER2 or EGFR. Am J Surg Pathol 2006; 30: 1097-104. doi:
10.1097/01.pas.000.021.3306.05811.b9.
- [38] Xu Z, Marko NF, Chao ST, et al. Relationship between HER2
status and prognosis in women with brain metastases from
breast cancer. Int J Radiat Oncol Biol Phys 2012; 82: e739-47.
doi: 10.1016/j.ijrobp.2011.06.1968.
- [39] Wang H, Zhang C, Zhang J, Kong L, Zhu H, Yu J. The prognosis
analysis of different metastasis pattern in patients with different
breast cancer subtypes: a SEER based study. Oncotarget 2017;
8: 26368-26379. doi: 10.18632/oncotarget.14300.
- [40] Collins LC, Martyniak A, Kandel MJ, et al. Basal cytokeratin
and epidermal growth factor receptor expression are not
predictive of BRCA1 mutation status in women with triplenegative
breast cancers. Am J Surg Pathol 2009; 33: 1093-7.
doi: 10.1097/PAS.0b013e31819c1c93.
- [41] Lim YJ, Lee SW, Choi N, et al. Failure patterns according to
molecular subtype in patients with invasive breast cancer
following postoperative adjuvant radiotherapy: long-term
outcomes in contemporary clinical practice. Breast Cancer
Res Treat 2017; 163: 555-563. doi: 10.1007/s10549.017.4206-8.
- [42] Heitz F, Harter P, Lueck HJ, et al. Triple-negative and HER2-
overexpressing breast cancers exhibit an elevated risk and an
earlier occurrence of cerebral metastases. Eur J Cancer 2009;
45: 2792-8. doi: 10.1016/j.ejca.2009.06.027.
- [43] Nam BH, Kim SY, Han HS, et al. Breast cancer subtypes and
survival in patients with brain metastases. Breast Cancer Res
2008; 10: R20. doi: 10.1186/bcr1870.
- [44] Niwińska A, Murawska M, Pogoda K. Breast cancer brain
metastases: differences in survival depending on biological
subtype, RPA RTOG prognostic class and systemic treatment
after whole-brain radiotherapy (WBRT). Ann Oncol 2010; 21:
942-8. doi: 10.1093/annonc/mdp407.
- [45] Sperduto PW, Kased N, Roberge D, et al. Effect of tumor
subtype on survival and the graded prognostic assessment
for patients with breast cancer and brain metastases. Int
J Radiat Oncol Biol Phys 2012; 82: 2111-7. doi: 10.1016/j.
ijrobp.2011.02.027.
- [46] Franciosi V, Cocconi G, Michiara M, et al. Front-line
chemotherapy with cisplatin and etoposide for patients with
brain metastases from breast carcinoma, nonsmall cell lung
carcinoma, or malignant melanoma: a prospective study.
Cancer 1999; 85: 1599-605. PMID: 10193952.
- [47] Rivera E, Meyers C, Groves M, et al. Phase I study of capecitabine
in combination with temozolomide in the treatment of
patients with brain metastases from breast carcinoma. Cancer
2006; 107: 1348-54. doi: 10.1002/cncr.22127.
- [48] Siena S, Crinò L, Danova M, et al. Dose-dense temozolomide
regimen for the treatment of brain metastases from melanoma,
breast cancer, or lung cancer not amenable to surgery or
radiosurgery: a multicenter phase II study. Ann Oncol 2010;
21: 655-61. doi: 10.1093/annonc/mdp343. Epub 2009 Sep 18.
- [49] Freedman RA, Bullitt E, Sun L, et al. A phase II study of
sagopilone (ZK 219477; ZK-EPO) in patients with breast
cancer and brain metastases. Clin Breast Cancer 2011;11: 376-
83. doi: 10.1016/j.clbc.2011.03.024.
- [50] Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck
N, Heinemann V. Ratio of trastuzumab levels in serum and
cerebrospinal fluid is altered in HER2-positive breast cancer
patients with brain metastases and impairment of blood-brain
barrier. Anticancer Drugs 2007; 18: 23-8. doi: 10.1097/01.
cad.000.023.6313.50833.ee.
- [51] Bartsch R, Rottenfusser A, Wenzel C, et al. Trastuzumab
prolongs overall survival in patients with brain metastases
from Her2 positive breast cancer. J Neurooncol 2007; 85: 311-
7. doi: 10.1007/s11060.007.9420-5.
- [52] Le Scodan R, Jouanneau L, Massard C, et al. Brain metastases
from breast cancer: prognostic significance of HER-2
overexpression, effect of Trastuzumab and cause of death.
BMC Cancer 2011; 11: 395. doi: 10.1186/1471-2407-11-395.
- [53] Lin NU, Diéras V, Paul D, et al. Multicenter phase II study
of lapatinib in patients with brain metastases from HER2-
positive breast cancer. Clin Cancer Res 2009; 15: 1452-9. doi:
10.1158/1078-0432.CCR-08-1080.
- [54] Miller JA, Kotecha R, Ahluwalia MS, et al. Overall survival and
the response to radiotherapy among molecular subtypes of
breast cancer brain metastases treated with targeted therapies.
Cancer 2017; 123: 2283-93. doi: 10.1002/cncr.30616.
- [55] Kim JM, Miller JA, Kotecha R, et al. Stereotactic radiosurgery
with concurrent HER2-directed therapy is associated with
improved objective response for breast cancer brain metastasis.
Neuro Oncol 2019; 21: 659-68. doi: 10.1093/neuonc/noz006.
- [56] Parsai S, Miller JA, Juloori A, et al. Stereotactic radiosurgery
with concurrent lapatinib is associated with improved local
control for HER2-positive breast cancer brain metastases.
J Neurosurg 2019; 132: 503-11. doi: 10.3171/2018.10.
JNS182340.
- [57] Yomo S, Hayashi M, Cho N. Impacts of HER2-overexpression
and molecular targeting therapy on the efficacy of
stereotactic radiosurgery for brain metastases from breast
cancer. J Neurooncol 2013; 112: 199-207. doi: 10.1007/
s11060.013.1046-1.
- [58] Parsai S, Miller JA, Juloori A, et al. Stereotactic radiosurgery
with concurrent lapatinib is associated with improved local
control for HER2-positive breast cancer brain metastases.
J Neurosurg 2019; 132: 503-11. doi: 10.3171/2018.10.
JNS182340.
- [59] Ou D, Cao L, Xu C, Kirova Y, Chen JY. Upfront brain
radiotherapy may improve survival for unfavorable prognostic
breast cancer brain metastasis patients with Breast-GPA 0-2.0.
Breast J 2019; 25: 1134-42. doi: 10.1111/tbj.13426.